Mosaic Therapeutics, a Cambridge, UK-based oncology therapeutics company, raised $28M in Series A funding.
Backers included Syncona Investment Management, and Cambridge Innovation Capital.
The company intends to use the funds to further advance its pipeline of targeted oncology therapies for biomarker-stratified populations, progressing its lead programs through preclinical development to IND-enabling studies.
Led by CEO Brian Gladsden, former Novartis Oncology SVP, Mosaic Therapeutics uses computational methods, combining large dataset mining with experimental approaches to identify and develop novel targeted therapies for drug discovery and targeting approach.
Mosaic’s proprietary platform applies research from co-founder Dr Mathew Garnett’s Translational Cancer Genomics Laboratory at the Wellcome Sanger Institute. Dr Garnett is a Senior Group Leader at Sanger with over 20 years’ experience in genomics and cancer therapeutics, with past achievements including co-discovery of BRAF mutations in cancer and Werner Syndrome helicase as a target in MSI tumours.
Alongside Dr Garnett, the Company was co-founded by Professor Emile Voest and Dr Adrian Ibrahim. Professor Voest is Professor of Medical Oncology, Chairman of the Board of Cancer Core Europe, Group Leader at the Netherlands Cancer Institute and Oncode Institute, and Independent Director of the Board of Sanofi S.A. Dr Ibrahim was formerly Head of Technology Translation at the Wellcome Sanger Institute, has 30 years’ experience across the discovery and development of cancer and genomics technologies, and has been involved in multiple genomics company spin-outs.
The company is a spin-out company from the Wellcome Sanger Institute, which provides it with access to scientific expertise, infrastructure and biological resources.
FinSMEs
04/04/2023